source: qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE@ 1490

Last change on this file since 1490 was 1490, checked in by Sam Habiel, 12 years ago

Stroke measures done

File size: 74.9 KB
RevLine 
[1490]1KIDS Distribution saved on Jul 18, 2012@11:48:37
2SDFGHJKSDFGHJKL
[1485]3**KIDS**:C0Q*1.0*3^
4
5**INSTALL NAME**
6C0Q*1.0*3
7"BLD",7936,0)
[1490]8C0Q*1.0*3^QUALITY MEASURES^0^3120718^y
[1485]9"BLD",7936,1,0)
10^^5^5^3120713^
11"BLD",7936,1,1,0)
12Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
13"BLD",7936,1,2,0)
142.0.
15"BLD",7936,1,3,0)
16
17"BLD",7936,1,4,0)
18Contains updated C0Q QUALITY MEASURES file containing the appropriate
19"BLD",7936,1,5,0)
20rule sets to use after each measure.
21"BLD",7936,4,0)
22^9.64PA^1130580001.101^1
23"BLD",7936,4,1130580001.101,0)
241130580001.101
25"BLD",7936,4,1130580001.101,222)
26y^y^f^^y^^y^o^n
27"BLD",7936,4,"B",1130580001.101,1130580001.101)
28
29"BLD",7936,6.3)
[1490]305
[1485]31"BLD",7936,"ABPKG")
32n
33"BLD",7936,"KRN",0)
34^9.67PA^779.2^20
35"BLD",7936,"KRN",.4,0)
36.4
37"BLD",7936,"KRN",.401,0)
38.401
39"BLD",7936,"KRN",.402,0)
40.402
41"BLD",7936,"KRN",.403,0)
42.403
43"BLD",7936,"KRN",.5,0)
44.5
45"BLD",7936,"KRN",.84,0)
46.84
47"BLD",7936,"KRN",3.6,0)
483.6
49"BLD",7936,"KRN",3.8,0)
503.8
51"BLD",7936,"KRN",9.2,0)
529.2
53"BLD",7936,"KRN",9.8,0)
549.8
55"BLD",7936,"KRN",19,0)
5619
57"BLD",7936,"KRN",19.1,0)
5819.1
59"BLD",7936,"KRN",101,0)
60101
61"BLD",7936,"KRN",409.61,0)
62409.61
63"BLD",7936,"KRN",771,0)
64771
65"BLD",7936,"KRN",779.2,0)
66779.2
67"BLD",7936,"KRN",870,0)
68870
69"BLD",7936,"KRN",8989.51,0)
708989.51
71"BLD",7936,"KRN",8989.52,0)
728989.52
73"BLD",7936,"KRN",8994,0)
748994
75"BLD",7936,"KRN","B",.4,.4)
76
77"BLD",7936,"KRN","B",.401,.401)
78
79"BLD",7936,"KRN","B",.402,.402)
80
81"BLD",7936,"KRN","B",.403,.403)
82
83"BLD",7936,"KRN","B",.5,.5)
84
85"BLD",7936,"KRN","B",.84,.84)
86
87"BLD",7936,"KRN","B",3.6,3.6)
88
89"BLD",7936,"KRN","B",3.8,3.8)
90
91"BLD",7936,"KRN","B",9.2,9.2)
92
93"BLD",7936,"KRN","B",9.8,9.8)
94
95"BLD",7936,"KRN","B",19,19)
96
97"BLD",7936,"KRN","B",19.1,19.1)
98
99"BLD",7936,"KRN","B",101,101)
100
101"BLD",7936,"KRN","B",409.61,409.61)
102
103"BLD",7936,"KRN","B",771,771)
104
105"BLD",7936,"KRN","B",779.2,779.2)
106
107"BLD",7936,"KRN","B",870,870)
108
109"BLD",7936,"KRN","B",8989.51,8989.51)
110
111"BLD",7936,"KRN","B",8989.52,8989.52)
112
113"BLD",7936,"KRN","B",8994,8994)
114
115"BLD",7936,"QUES",0)
116^9.62^^
117"BLD",7936,"REQB",0)
118^9.611^2^2
119"BLD",7936,"REQB",1,0)
120C0Q*1.0*2^2
121"BLD",7936,"REQB",2,0)
122QUALITY MEASURES 1.0^2
123"BLD",7936,"REQB","B","C0Q*1.0*2",1)
124
125"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
126
127"DATA",1130580001.101,1,0)
128M1^^^2.16.840.1.113883.3.249.11.2
129"DATA",1130580001.101,1,1)
130CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
131"DATA",1130580001.101,1,4)
132PQRI-1
133"DATA",1130580001.101,1,5)
134Hemoglobin A1c Poor Control in Diabetes Mellitus
135"DATA",1130580001.101,1,6,0)
136^^2^2^3101013^
137"DATA",1130580001.101,1,6,1,0)
138Percentage of patients 18 through 75 years with diabetes melli
139"DATA",1130580001.101,1,6,2,0)
140tus who had most recent hemoglobin A1C greater than 9.0%
141"DATA",1130580001.101,1,7)
142^^^^
143"DATA",1130580001.101,2,0)
144M5^^^2.16.840.1.113883.3.249.11.5
145"DATA",1130580001.101,2,1)
146CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
147"DATA",1130580001.101,2,4)
148PQRI-5
149"DATA",1130580001.101,2,5)
150Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
151"DATA",1130580001.101,2,6,0)
152^^2^2^3101013^
153"DATA",1130580001.101,2,6,1,0)
154Percentage of patients 18 years and older with a diagnosis of
155"DATA",1130580001.101,2,6,2,0)
156heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy
157"DATA",1130580001.101,2,7)
158^^^^
159"DATA",1130580001.101,3,0)
160M112^^^2.16.840.1.113883.3.249.11.9
161"DATA",1130580001.101,3,1)
162Measure #112: Preventive Care and Screening: Screening Mammography
163"DATA",1130580001.101,3,4)
164PQRI-112
165"DATA",1130580001.101,3,5)
166Screening Mammography
167"DATA",1130580001.101,3,6,0)
168^1130580001.111^2^2^3101014^^
169"DATA",1130580001.101,3,6,1,0)
170Percentage of womaen aged 40 through 69 years who had a mammog
171"DATA",1130580001.101,3,6,2,0)
172ram to screen for breast cancer within 24 months
173"DATA",1130580001.101,3,7)
174^^^^
175"DATA",1130580001.101,4,0)
176M124^^^2.16.840.1.113883.3.249.11.11
177"DATA",1130580001.101,4,1)
178Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
179"DATA",1130580001.101,4,4)
180PQRI-124
181"DATA",1130580001.101,4,5)
182Adoption/Use of Electronic Health Records (EHR)
183"DATA",1130580001.101,4,6,0)
184^^3^3^3101013^
185"DATA",1130580001.101,4,6,1,0)
186Documents whether provider has adopted and is using health inf
187"DATA",1130580001.101,4,6,2,0)
188ormation technology. To qualify, the provider must havea adopted and be
189"DATA",1130580001.101,4,6,3,0)
190using a certified/qualified electronic health record (EHR)
191"DATA",1130580001.101,4,7)
192^^^^
193"DATA",1130580001.101,5,0)
194M128^^^2.16.840.1.113883.3.249.11.54
195"DATA",1130580001.101,5,1)
196Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
197"DATA",1130580001.101,5,4)
198PQRI-128
199"DATA",1130580001.101,5,5)
200Body Mass Index (BMI) Screening and Follow-Up
201"DATA",1130580001.101,5,6,0)
202^1130580001.111^5^5^3101014^^
203"DATA",1130580001.101,5,6,1,0)
204Percentage of patients aged 18 yesrs and older with a calculate BMI in
205"DATA",1130580001.101,5,6,2,0)
206the past 6 months or during the current visit documented in the medical
207"DATA",1130580001.101,5,6,3,0)
208record and if the most recent BMI is ourtide parameters, a follow-up plan
209"DATA",1130580001.101,5,6,4,0)
210is documented. Ages 65 and older BMI equal to or greater than 30 or less
211"DATA",1130580001.101,5,6,5,0)
212than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5
213"DATA",1130580001.101,5,7)
214^^^^
215"DATA",1130580001.101,6,0)
216M47^^^2.16.840.1.113883.3.249.11.52
217"DATA",1130580001.101,6,1)
218Measure #47: Advance Care Plan
219"DATA",1130580001.101,6,4)
220PQRI-47
221"DATA",1130580001.101,6,5)
222Advance Care Plan
223"DATA",1130580001.101,6,6,0)
224^1130580001.111^5^5^3101014^^^
225"DATA",1130580001.101,6,6,1,0)
226Percentage of patients age 65 and older who have an advanced care plan or
227"DATA",1130580001.101,6,6,2,0)
228surrogate decision maker documented in the medical record or documented
229"DATA",1130580001.101,6,6,3,0)
230in the medical record that an advance care plan was discussed but the
231"DATA",1130580001.101,6,6,4,0)
232patient did not wish or was not able to name a surrogate decision maker
233"DATA",1130580001.101,6,6,5,0)
234or provide an advance care plan.
235"DATA",1130580001.101,6,7)
236^^^^
237"DATA",1130580001.101,7,0)
238M48^^^2.16.840.1.113883.3.249.11.53
239"DATA",1130580001.101,7,1)
240Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
241"DATA",1130580001.101,7,4)
242PQRI-48
243"DATA",1130580001.101,7,5)
244Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
245"DATA",1130580001.101,7,6,0)
246^^3^3^3101013^
247"DATA",1130580001.101,7,6,1,0)
248Percentage of patients equal to or older than 65 years of age at the
249"DATA",1130580001.101,7,6,2,0)
250beginning of the measurement perion who were assesed for the presence or
251"DATA",1130580001.101,7,6,3,0)
252absence of urinary incontinence within 12 months
253"DATA",1130580001.101,7,7)
254^^^^
255"DATA",1130580001.101,8,0)
256M2^^^2.16.840.1.113883.3.249.11.3
257"DATA",1130580001.101,8,1)
258Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
259"DATA",1130580001.101,8,4)
260PQRI-2
261"DATA",1130580001.101,8,5)
262Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
263"DATA",1130580001.101,8,6,0)
264^^2^2^3101013^
265"DATA",1130580001.101,8,6,1,0)
266Percentage of patients 18 through 75 years with diabetes melli
267"DATA",1130580001.101,8,6,2,0)
268tus who had most recent LDL-C level in control (less than 100 mg./dL)
269"DATA",1130580001.101,8,7)
270^^^^
271"DATA",1130580001.101,9,0)
272M3^^^2.16.840.1.113883.3.249.11.4
273"DATA",1130580001.101,9,1)
274CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template
275"DATA",1130580001.101,9,4)
276PQRI-3
277"DATA",1130580001.101,9,5)
278High Blood Pressure Control in Diabetes Mellitus
279"DATA",1130580001.101,9,6,0)
280^^2^2^3101013^
281"DATA",1130580001.101,9,6,1,0)
282Percentage of patients 18 through 75 years with diabetes melli
283"DATA",1130580001.101,9,6,2,0)
284tus who had most recent blood pressure in control (less than 140/80 mmHg)
285"DATA",1130580001.101,9,7)
286^^^^
287"DATA",1130580001.101,10,0)
288M7^^^2.16.840.1.113883.3.249.11.6
289"DATA",1130580001.101,10,1)
290CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
291"DATA",1130580001.101,10,4)
292PQRI-7
293"DATA",1130580001.101,10,5)
294Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
295"DATA",1130580001.101,10,6,0)
296^^3^3^3101013^
297"DATA",1130580001.101,10,6,1,0)
298Percentage of patients aged 18 years and older with a diagnosis of
299"DATA",1130580001.101,10,6,2,0)
300coronary artery disease and a prior MI who where prescribed beta-blocker
301"DATA",1130580001.101,10,6,3,0)
302therapy
303"DATA",1130580001.101,10,7)
304^^^^
305"DATA",1130580001.101,11,0)
306M110^^^2.16.840.1.113883.3.249.11.7
307"DATA",1130580001.101,11,1)
308Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
309"DATA",1130580001.101,11,4)
310PQRI-110
311"DATA",1130580001.101,11,5)
312Influenza Immunization for Patients >= 50 Years
313"DATA",1130580001.101,11,6,0)
314^1130580001.111^2^2^3101014^^
315"DATA",1130580001.101,11,6,1,0)
316Percentage of patients aged 50 years and older who received an
317"DATA",1130580001.101,11,6,2,0)
318 influenza immunization during the flu season (September through February)
319"DATA",1130580001.101,11,7)
320^^^^
321"DATA",1130580001.101,12,0)
322M111^^^2.16.840.1.113883.3.249.11.8
323"DATA",1130580001.101,12,1)
324Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
325"DATA",1130580001.101,12,4)
326PQRI-111
327"DATA",1130580001.101,12,5)
328Pneumonia Vaccination for Patients 65 Years and Older
329"DATA",1130580001.101,12,6,0)
330^^2^2^3101013^
331"DATA",1130580001.101,12,6,1,0)
332Percentage of patients afed 65 years and older who have ever r
333"DATA",1130580001.101,12,6,2,0)
334eceived a pneumoccal vaccine
335"DATA",1130580001.101,12,7)
336^^^^
337"DATA",1130580001.101,13,0)
338M113^^^2.16.840.1.113883.3.249.11.10
339"DATA",1130580001.101,13,1)
340Measure #113: Preventive Care and Screening: Colorectal Cancer Screening
341"DATA",1130580001.101,13,4)
342PQRI-113
343"DATA",1130580001.101,13,5)
344Colorectal Cancer Screening
345"DATA",1130580001.101,13,6,0)
346^^2^2^3101013^
347"DATA",1130580001.101,13,6,1,0)
348Percentage of patients aged 50 through 80 who received the app
349"DATA",1130580001.101,13,6,2,0)
350ropriate colorectal cancer screening
351"DATA",1130580001.101,13,7)
352^^^^
353"DATA",1130580001.101,14,0)
354M39^^^2.16.840.1.113883.3.249.11.51
355"DATA",1130580001.101,14,1)
356Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
357"DATA",1130580001.101,14,4)
358PQRI-39
359"DATA",1130580001.101,14,5)
360Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
361"DATA",1130580001.101,14,6,0)
362^^3^3^3101013^
363"DATA",1130580001.101,14,6,1,0)
364Percentage of patients who had a DXA measurement ordered or pe
365"DATA",1130580001.101,14,6,2,0)
366rformed at least once since age 60 or pharmacologic therapy prescribed
367"DATA",1130580001.101,14,6,3,0)
368within 12 months before the end of the measurement period
369"DATA",1130580001.101,14,7)
370^^^^
371"DATA",1130580001.101,16,0)
372M173^^^2.16.840.1.113883.3.249.11.55
373"DATA",1130580001.101,16,1)
374Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
375"DATA",1130580001.101,16,4)
376PQRI-173
377"DATA",1130580001.101,16,5)
378Preventive Care and Screening: Unhealthy Alcohol Use - Screening
379"DATA",1130580001.101,16,6,0)
380^^2^2^3101013^
381"DATA",1130580001.101,16,6,1,0)
382Percentage of patients aged 18 years and older who were screen
383"DATA",1130580001.101,16,6,2,0)
384ed for unhealthy alcohol use using a systematic method within 24 months
385"DATA",1130580001.101,16,7)
386^^^^
387"DATA",1130580001.101,17,0)
388M0013^^^2.16.840.1.113883.3.249.11.56
389"DATA",1130580001.101,17,1)
390Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template
391"DATA",1130580001.101,17,4)
392PQRI-13
393"DATA",1130580001.101,17,5)
394Hypertension (HTN): Blood Pressure Measurement
395"DATA",1130580001.101,17,6,0)
396^1130580001.111^3^3^3110412^^
397"DATA",1130580001.101,17,6,1,0)
398Percentage of patients aged 18 years and older with a diagnosi
399"DATA",1130580001.101,17,6,2,0)
400s of hypertension in the beginning of the measurement period with a blood
401"DATA",1130580001.101,17,6,3,0)
402pressure recorded
403"DATA",1130580001.101,17,7)
404^^^^
405"DATA",1130580001.101,18,0)
406M0022^^^2.16.840.1.113883.3.249.11.57
407"DATA",1130580001.101,18,1)
408Measure #0022: Drugs to be avoided in the Elderly
409"DATA",1130580001.101,18,4)
410PQRI-22
411"DATA",1130580001.101,18,5)
412Drugs to be avoided in the elderly
413"DATA",1130580001.101,18,6,0)
414^^2^2^3101013^
415"DATA",1130580001.101,18,6,1,0)
416Percentage of patients aged 65 years and older who received at least one
417"DATA",1130580001.101,18,6,2,0)
418drug to be avoided in the elderly in the measurement period
419"DATA",1130580001.101,18,7)
420^^^^
421"DATA",1130580001.101,19,0)
422M0028^^^2.16.840.1.113883.3.249.11.59
423"DATA",1130580001.101,19,1)
424Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
425"DATA",1130580001.101,19,4)
426PQRI-28
427"DATA",1130580001.101,19,5)
428Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
429"DATA",1130580001.101,19,6,0)
430^^4^4^3101013^
431"DATA",1130580001.101,19,6,1,0)
432Percentage of patients aged 18 years of older who were screene
433"DATA",1130580001.101,19,6,2,0)
434d about tobacco use at least once during the two year measurement period
435"DATA",1130580001.101,19,6,3,0)
436AND who received smoking cessation counseling if identified as a tobacco
437"DATA",1130580001.101,19,6,4,0)
438user
439"DATA",1130580001.101,19,7)
440^^^^
441"DATA",1130580001.101,20,0)
442M0038^^^2.16.840.1.113883.3.249.11.60
443"DATA",1130580001.101,20,1)
444Measure #0038: Childhood Immunization Status
445"DATA",1130580001.101,20,4)
446PQRI-38
447"DATA",1130580001.101,20,5)
448Childhood immumnization status
449"DATA",1130580001.101,20,6,0)
450^^4^4^3101013^
451"DATA",1130580001.101,20,6,1,0)
452Percentage of children who turn two years of age during the me
453"DATA",1130580001.101,20,6,2,0)
454asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza
455"DATA",1130580001.101,20,6,3,0)
456type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal
457"DATA",1130580001.101,20,6,4,0)
458conjugate vaccines by their second birthday
459"DATA",1130580001.101,20,7)
460^^^^
461"DATA",1130580001.101,21,0)
462M0024^^
463"DATA",1130580001.101,21,7)
464^^^^
465"DATA",1130580001.101,22,0)
466TEST M0028A^^^2.16.840.1.113883.3.249.11.59
467"DATA",1130580001.101,22,1)
468Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
469"DATA",1130580001.101,22,4)
470PQRI-28
471"DATA",1130580001.101,22,5)
472Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
473"DATA",1130580001.101,22,6,0)
474^1130580001.111^4^4^3110427^^^^
475"DATA",1130580001.101,22,6,1,0)
476Percentage of patients aged 18 years of older who were screene
477"DATA",1130580001.101,22,6,2,0)
478d about tobacco use at least once during the two year measurement period
479"DATA",1130580001.101,22,6,3,0)
480AND who received smoking cessation counseling if identified as a tobacco
481"DATA",1130580001.101,22,6,4,0)
482user
483"DATA",1130580001.101,22,7)
484^^^^
485"DATA",1130580001.101,23,0)
486MU HOS NQF 0495^^
487"DATA",1130580001.101,23,1)
488ED THROUGHPUT ARRIVAL TO DEPARTURE
489"DATA",1130580001.101,23,5)
490ED THROUGHPUT ARRIVAL TO DEPARTURE
491"DATA",1130580001.101,23,6,0)
492^1130580001.111^3^3^3110430^^^^
493"DATA",1130580001.101,23,6,1,0)
494Median time from emergency department arrival to time of departure from
495"DATA",1130580001.101,23,6,2,0)
496the emergency room for patients admitted to the facility from the
497"DATA",1130580001.101,23,6,3,0)
498emergency department
499"DATA",1130580001.101,23,7)
[1489]500NQF0495^^^^^^88^165
[1485]501"DATA",1130580001.101,24,0)
502MU HOS NQF 0497^^
503"DATA",1130580001.101,24,1)
504ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
505"DATA",1130580001.101,24,5)
506ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
507"DATA",1130580001.101,24,6,0)
508^^3^3^3110430^
509"DATA",1130580001.101,24,6,1,0)
510Median time from admit decision time to time of departure from the
511"DATA",1130580001.101,24,6,2,0)
512emergency department of emergency department patients admitted to
513"DATA",1130580001.101,24,6,3,0)
514inpatient status
515"DATA",1130580001.101,24,7)
[1489]516NQF0497^^^^^^90^168
[1485]517"DATA",1130580001.101,25,0)
518MU HOS NQF 0435^^
519"DATA",1130580001.101,25,1)
520Ischemic stroke.Discharge on anti-thrombotics
521"DATA",1130580001.101,25,5)
522 Ischemic stroke.Discharge on anti-thrombotic
523"DATA",1130580001.101,25,6,0)
524^^2^2^3110430^
525"DATA",1130580001.101,25,6,1,0)
526Ischemic stroke patients prescribed antithrombotic therapy at hospital
527"DATA",1130580001.101,25,6,2,0)
528discharge
529"DATA",1130580001.101,25,7)
[1490]530NQF0435^^^^^^114^115
[1485]531"DATA",1130580001.101,26,0)
532MU HOS NQF 0436^^
533"DATA",1130580001.101,26,1)
534 Ischemic stroke.Anticoagulation for A-fib/flutter
535"DATA",1130580001.101,26,5)
536Ischemic stroke.Anticoagulation for A-fib/flutter
537"DATA",1130580001.101,26,6,0)
538^1130580001.111^2^2^3110430^^^
539"DATA",1130580001.101,26,6,1,0)
540 Ischemic stroke patients with atrial fibrillation/flutter who are
541"DATA",1130580001.101,26,6,2,0)
542prescribed anticoagulation therapy at hospital discharge
543"DATA",1130580001.101,26,7)
[1490]544NQF0436^^^^^^116^117
[1485]545"DATA",1130580001.101,27,0)
546MU HOS NQF 0437^^
547"DATA",1130580001.101,27,1)
548 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
549"DATA",1130580001.101,27,5)
550Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
551"DATA",1130580001.101,27,6,0)
552^^3^3^3110430^
553"DATA",1130580001.101,27,6,1,0)
554Acute ischemic stroke patients who arrive at this hospital within 2
555"DATA",1130580001.101,27,6,2,0)
556hours of time last known well and for whom IV t-PA was initiated at this
557"DATA",1130580001.101,27,6,3,0)
558hospital within 3 hours of time last known well.
559"DATA",1130580001.101,27,7)
[1490]560NQF0437^^^^^^119^118
[1485]561"DATA",1130580001.101,28,0)
562MU HOS NQF 0438^^
563"DATA",1130580001.101,28,1)
564Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
565"DATA",1130580001.101,28,5)
566Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
567"DATA",1130580001.101,28,6,0)
568^^2^2^3110430^
569"DATA",1130580001.101,28,6,1,0)
570Ischemic stroke patients administered antithrombotic therapy by the
571"DATA",1130580001.101,28,6,2,0)
572end of hospital day 2.
573"DATA",1130580001.101,28,7)
[1490]574NQF0438^^^^^^120^121
[1485]575"DATA",1130580001.101,29,0)
576MU HOS NQF 0439^^
577"DATA",1130580001.101,29,1)
578Ischemic stroke.Discharge on statins
579"DATA",1130580001.101,29,5)
580Ischemic stroke.Discharge on statins
581"DATA",1130580001.101,29,6,0)
582^^3^3^3110430^
583"DATA",1130580001.101,29,6,1,0)
584Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
585"DATA",1130580001.101,29,6,2,0)
586who were on a lipid-lowering medication prior to hospital arrival are
587"DATA",1130580001.101,29,6,3,0)
588prescribed statin medication at hospital discharge
589"DATA",1130580001.101,29,7)
[1490]590NQF0439^^^^^^122^123
[1485]591"DATA",1130580001.101,30,0)
592MU HOS NQF 0440^^
593"DATA",1130580001.101,30,1)
594Ischemic or hemorrhagic stroke.Stroke education
595"DATA",1130580001.101,30,5)
596Ischemic or hemorrhagic stroke.Stroke education
597"DATA",1130580001.101,30,6,0)
598^^5^5^3110430^
599"DATA",1130580001.101,30,6,1,0)
600Ischemic or hemorrhagic stroke patients or their caregivers who were
601"DATA",1130580001.101,30,6,2,0)
602given educational materials during the hospital stay addressing all of the
603"DATA",1130580001.101,30,6,3,0)
604following: activation of emergency medical system, need for follow-up
605"DATA",1130580001.101,30,6,4,0)
606after discharge, medications prescribed at discharge, risk factors for
607"DATA",1130580001.101,30,6,5,0)
608stroke, and warning signs and symptoms of stroke.
609"DATA",1130580001.101,30,7)
[1490]610NQF0440^^^^^^124^125
[1485]611"DATA",1130580001.101,31,0)
612MU HOS NQF 0441^^
613"DATA",1130580001.101,31,1)
614Ischemic or hemorrhagic stroke.Rehabilitation assessment
615"DATA",1130580001.101,31,5)
616Ischemic or hemorrhagic stroke.Rehabilitation assessment
617"DATA",1130580001.101,31,6,0)
618^^2^2^3110430^
619"DATA",1130580001.101,31,6,1,0)
620Ischemic or hemorrhagic stroke patients who were assessed for
621"DATA",1130580001.101,31,6,2,0)
622rehabilitation services.
623"DATA",1130580001.101,31,7)
[1490]624NQF0441^^^^^^126^127
[1485]625"DATA",1130580001.101,32,0)
626MU HOS NQF 0371^^
627"DATA",1130580001.101,32,1)
628VTE prophylaxis within 24 hours of arrival
629"DATA",1130580001.101,32,5)
630VTE prophylaxis within 24 hours of arrival
631"DATA",1130580001.101,32,6,0)
632^^4^4^3110430^
633"DATA",1130580001.101,32,6,1,0)
634This measure assesses the number of patients who received VTE prophylaxis
635"DATA",1130580001.101,32,6,2,0)
636or have documentation why no VTE prophylaxis was given the day of or the
637"DATA",1130580001.101,32,6,3,0)
638day after hospital admission or surgery end date for surgeries that start
639"DATA",1130580001.101,32,6,4,0)
640the day of or the day after hospital admission.
641"DATA",1130580001.101,32,7)
642NQF0371^^^^
643"DATA",1130580001.101,33,0)
644MU HOS NQF 0372^^
645"DATA",1130580001.101,33,1)
646ICU VTE prophylaxis
647"DATA",1130580001.101,33,5)
648ICU VTE prophylaxis
649"DATA",1130580001.101,33,6,0)
650^^5^5^3110430^
651"DATA",1130580001.101,33,6,1,0)
652This measure assesses the number of patients who received VTE prophylaxis
653"DATA",1130580001.101,33,6,2,0)
654or have documentation why no VTE prophylaxis was given the day of or the
655"DATA",1130580001.101,33,6,3,0)
656day after the initial admission (or transfer) to the Intensive Care Unit
657"DATA",1130580001.101,33,6,4,0)
658(ICU) or surgery end date for surgeries that start the day of or the day
659"DATA",1130580001.101,33,6,5,0)
660after ICU admission (or transfer).
661"DATA",1130580001.101,33,7)
662NQF0372^^^^
663"DATA",1130580001.101,34,0)
664MU HOS NQF 0373^^
665"DATA",1130580001.101,34,1)
666Anticoagulation overlap therapy
667"DATA",1130580001.101,34,5)
668Anticoagulation overlap therapy
669"DATA",1130580001.101,34,6,0)
670^^8^8^3110430^
671"DATA",1130580001.101,34,6,1,0)
672This measure assesses the number of patients diagnosed with confirmed VTE
673"DATA",1130580001.101,34,6,2,0)
674who received an overlap of parenteral (intravenous [IV] or subcutaneous
675"DATA",1130580001.101,34,6,3,0)
676[subcu]) anticoagulation and warfarin therapy. For patients who received
677"DATA",1130580001.101,34,6,4,0)
678less than five days of overlap therapy, they must be discharged on both
679"DATA",1130580001.101,34,6,5,0)
680medications. Overlap therapy must be administered for at least five days
681"DATA",1130580001.101,34,6,6,0)
682with an international normalized ratio (INR) . 2 prior to discontinuation
683"DATA",1130580001.101,34,6,7,0)
684of the parenteral anticoagulation therapy or the patient must be
685"DATA",1130580001.101,34,6,8,0)
686discharged on both medications.
687"DATA",1130580001.101,34,7)
688NQF0373^^^^
689"DATA",1130580001.101,35,0)
690MU HOS NQF 0374^^
691"DATA",1130580001.101,35,1)
692Platelet monitoring on unfractionated heparin
693"DATA",1130580001.101,35,5)
694Platelet monitoring on unfractionated heparin
695"DATA",1130580001.101,35,6,0)
696^^10^10^3110430^
697"DATA",1130580001.101,35,6,1,0)
698This measure assesses the number of patients diagnosed with confirmed VTE
699"DATA",1130580001.101,35,6,2,0)
700who received intravenous (IV) UFH therapy dosages AND had their platelet
701"DATA",1130580001.101,35,6,3,0)
702counts monitored using defined parameters such as a nomogram or
703"DATA",1130580001.101,35,6,4,0)
704protocol This measure assesses the number of patients diagnosed with
705"DATA",1130580001.101,35,6,5,0)
706confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
707"DATA",1130580001.101,35,6,6,0)
708their platelet counts monitored using defined parameters such as a
709"DATA",1130580001.101,35,6,7,0)
710nomogram or protocol This measure assesses the number of patients
711"DATA",1130580001.101,35,6,8,0)
712diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
713"DATA",1130580001.101,35,6,9,0)
714dosages AND had their platelet counts monitored using defined parameters
715"DATA",1130580001.101,35,6,10,0)
716such as a nomogram or protocol
717"DATA",1130580001.101,35,7)
718NQF0374^^^^
719"DATA",1130580001.101,36,0)
720MU HOS NQF 0375^^
721"DATA",1130580001.101,36,1)
722VTE discharge instructions
723"DATA",1130580001.101,36,5)
724VTE discharge instructions
725"DATA",1130580001.101,36,6,0)
726^^11^11^3110430^
727"DATA",1130580001.101,36,6,1,0)
728This measure assesses the number of patients diagnosed with confirmed VTE
729"DATA",1130580001.101,36,6,2,0)
730that are discharged to home, to home with home health, home hospice or
731"DATA",1130580001.101,36,6,3,0)
732discharged/transferred to court/law enforcement on warfarin with written
733"DATA",1130580001.101,36,6,4,0)
734discharge instructions that address all four criteria: compliance issues,
735"DATA",1130580001.101,36,6,5,0)
736dietary advice, follow-up This measure assesses the number of patients
737"DATA",1130580001.101,36,6,6,0)
738diagnosed with confirmed VTE that are discharged to home, to home with
739"DATA",1130580001.101,36,6,7,0)
740home health, home hospice or discharged/transferred to court/law
741"DATA",1130580001.101,36,6,8,0)
742enforcement on warfarin with written discharge instructions that address
743"DATA",1130580001.101,36,6,9,0)
744all four criteria: compliance issues, dietary advice, follow-up
745"DATA",1130580001.101,36,6,10,0)
746monitoring, and information about the potential for adverse drug
747"DATA",1130580001.101,36,6,11,0)
748reactions/interactions.
749"DATA",1130580001.101,36,7)
750NQF0375^^^^
751"DATA",1130580001.101,37,0)
752MU HOS NQF 0376^^
753"DATA",1130580001.101,37,1)
754Incidence of potentially preventable VTE
755"DATA",1130580001.101,37,5)
756Incidence of potentially preventable VTE
757"DATA",1130580001.101,37,6,0)
758^^4^4^3110430^
759"DATA",1130580001.101,37,6,1,0)
760This measure assesses the number of patients diagnosed with confirmed VTE
761"DATA",1130580001.101,37,6,2,0)
762during hospitalization (not present on arrival) who did not receive VTE
763"DATA",1130580001.101,37,6,3,0)
764prophylaxis between hospital admission and the day before the VTE
765"DATA",1130580001.101,37,6,4,0)
766diagnostic testing order date.
767"DATA",1130580001.101,37,7)
768NQF0376^^^^
769"DATA",1130580001.101,38,0)
77012^^
771"DATA",1130580001.101,38,7)
772^^^^
773"DATA",1130580001.101,39,0)
774MU EP NQF 0421^^
775"DATA",1130580001.101,39,1)
776NQF0421 Adult Weight Screening and Follow-Up
777"DATA",1130580001.101,39,5)
778NQF0421 Adult Weight Screening and Follow-Up
779"DATA",1130580001.101,39,6,0)
780^1130580001.111^6^6^3110628^^^^
781"DATA",1130580001.101,39,6,1,0)
782Percentage of patients aged 18
783"DATA",1130580001.101,39,6,2,0)
784years and older with a calculated BMI in the past
785"DATA",1130580001.101,39,6,3,0)
786six months or during the current visit documented in
787"DATA",1130580001.101,39,6,4,0)
788the medical record AND if the most recent BMI is
789"DATA",1130580001.101,39,6,5,0)
790outside parameters, a follow-up plan is
791"DATA",1130580001.101,39,6,6,0)
792documented.
793"DATA",1130580001.101,39,7)
794NQF0421^^^^
795"DATA",1130580001.101,40,0)
796MU EP NQF 0013^^
797"DATA",1130580001.101,40,1)
798NQF0013 Hypertension: Blood Pressure Measurement
799"DATA",1130580001.101,40,5)
800NQF0013 Hypertension: Blood Pressure Measurement
801"DATA",1130580001.101,40,6,0)
802^1130580001.111^4^4^3120712^^^
803"DATA",1130580001.101,40,6,1,0)
804Percentage of patient visits for patients
805"DATA",1130580001.101,40,6,2,0)
806aged 18 years and older with a diagnosis of hypertension
807"DATA",1130580001.101,40,6,3,0)
808who have been seen for at least 2 office visits, with blood
809"DATA",1130580001.101,40,6,4,0)
810pressure (BP) recorded
811"DATA",1130580001.101,40,7)
812NQF0013^^^^^^142^167
813"DATA",1130580001.101,41,0)
814MU EP NQF 0028A^^
815"DATA",1130580001.101,41,1)
816NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
817"DATA",1130580001.101,41,5)
818NQF0028A Tobacco Use Assessment
819"DATA",1130580001.101,41,6,0)
820^1130580001.111^7^7^3110625^^^
821"DATA",1130580001.101,41,6,1,0)
822 Percentage of patients aged 18 years and
823"DATA",1130580001.101,41,6,2,0)
824older who have been seen for at least 2 office visits who
825"DATA",1130580001.101,41,6,3,0)
826were queried about tobacco use one or more times within
827"DATA",1130580001.101,41,6,4,0)
82824 months b. Percentage of patients aged 18 years and
829"DATA",1130580001.101,41,6,5,0)
830older identified as tobacco users within the past 24
831"DATA",1130580001.101,41,6,6,0)
832months and have been seen for at least 2 office visits,
833"DATA",1130580001.101,41,6,7,0)
834who received cessation intervention.
835"DATA",1130580001.101,41,7)
836NQF0028A^^^^^^157^160
837"DATA",1130580001.101,42,0)
838MU EP NQF 0041^^
839"DATA",1130580001.101,42,1)
840Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
841"DATA",1130580001.101,42,5)
842NQF0041 Influenza Immunization 50 years and older
843"DATA",1130580001.101,42,6,0)
844^^4^4^3110430^
845"DATA",1130580001.101,42,6,1,0)
846Percentage of patients aged 50 years
847"DATA",1130580001.101,42,6,2,0)
848and older who received an influenza immunization
849"DATA",1130580001.101,42,6,3,0)
850during the flu season (September through
851"DATA",1130580001.101,42,6,4,0)
852February).
853"DATA",1130580001.101,42,7)
854NQF0041^^^^^^242^243
855"DATA",1130580001.101,43,0)
856MU EP NQF 0024^^
857"DATA",1130580001.101,43,1)
858NQF0024 Weight Assessment and Counseling for Children and Adolescents
859"DATA",1130580001.101,43,5)
860NQF0024 Weight Assessment and Counseling for Children and Adolescents
861"DATA",1130580001.101,43,6,0)
862^1130580001.111^6^6^3120713^^
863"DATA",1130580001.101,43,6,1,0)
864Percentage of patients 2 -17 years of age
865"DATA",1130580001.101,43,6,2,0)
866who had an outpatient visit with a Primary Care Physician
867"DATA",1130580001.101,43,6,3,0)
868(PCP) or OB/GYN and who had evidence of BMI
869"DATA",1130580001.101,43,6,4,0)
870percentile documentation, counseling for nutrition and
871"DATA",1130580001.101,43,6,5,0)
872counseling for physical activity during the measurement
873"DATA",1130580001.101,43,6,6,0)
874year.
875"DATA",1130580001.101,43,7)
876NQF0024^^^^^^151^149
877"DATA",1130580001.101,44,0)
878MU EP NQF 0038^^
879"DATA",1130580001.101,44,1)
880Childhood Immunization Status
881"DATA",1130580001.101,44,5)
882Childhood Immunization Status
883"DATA",1130580001.101,44,6,0)
884^^14^14^3110430^
885"DATA",1130580001.101,44,6,1,0)
886Percentage of children 2 years of age who
887"DATA",1130580001.101,44,6,2,0)
888had four diphtheria, tetanus and acellular pertussis
889"DATA",1130580001.101,44,6,3,0)
890(DTaP); three polio(IPV), one measles, ,mumps and
891"DATA",1130580001.101,44,6,4,0)
892rubella (MMR); two H influenza type B (HiB); three
893"DATA",1130580001.101,44,6,5,0)
894Percentage of children 2 years of age who
895"DATA",1130580001.101,44,6,6,0)
896had four diphtheria, tetanus and acellular pertussis
897"DATA",1130580001.101,44,6,7,0)
898(DTaP); three polio(IPV), one measles, ,mumps and
899"DATA",1130580001.101,44,6,8,0)
900rubella (MMR); two H influenza type B (HiB); three
901"DATA",1130580001.101,44,6,9,0)
902hepatitis B (Hep B); one chicken pox (VZV); four
903"DATA",1130580001.101,44,6,10,0)
904pneumococcal conjugate (PCV); two hepatitis A (Hep A);
905"DATA",1130580001.101,44,6,11,0)
906two or three rotavirus (RV); and two influenza (flu)
907"DATA",1130580001.101,44,6,12,0)
908vaccines by their second birthday. The measure
909"DATA",1130580001.101,44,6,13,0)
910calculates a rate for each vaccine and nine separate
911"DATA",1130580001.101,44,6,14,0)
912combination rates.
913"DATA",1130580001.101,44,7)
914NQF0038^^^^
915"DATA",1130580001.101,45,0)
916MU EP NQF 0059^^
917"DATA",1130580001.101,45,1)
918Diabetes: Hemoglobin A1c Poor Contro
919"DATA",1130580001.101,45,5)
920Diabetes: NQF0059 Hemoglobin A1c Poor Control
921"DATA",1130580001.101,45,6,0)
[1486]922^1130580001.111^2^2^3120716^^
[1485]923"DATA",1130580001.101,45,6,1,0)
924Percentage of patients 18 - 75 years of age with diabetes (type 1
925"DATA",1130580001.101,45,6,2,0)
926or type 2) who had hemoglobin A1c > 9.0%.
927"DATA",1130580001.101,45,7)
[1486]928NQF0059^^^^^^260^258
[1485]929"DATA",1130580001.101,46,0)
930MU EP NQF 0064^^
931"DATA",1130580001.101,46,1)
932Diabetes: Low Density Lipoprotein (LDL) Management and Control
933"DATA",1130580001.101,46,5)
934NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
935"DATA",1130580001.101,46,6,0)
936^^3^3^3110430^
937"DATA",1130580001.101,46,6,1,0)
938Percentage of patients 18-75 years of age with diabetes (type 1
939"DATA",1130580001.101,46,6,2,0)
940or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
941"DATA",1130580001.101,46,6,3,0)
942of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
943"DATA",1130580001.101,46,7)
[1486]944NQF0064^^^^^^248^258
[1485]945"DATA",1130580001.101,47,0)
946MU EP NQF 0061^^
947"DATA",1130580001.101,47,1)
948Blood Pressure Management
949"DATA",1130580001.101,47,5)
950NQF0061 Diabetes: Blood Pressure Management
951"DATA",1130580001.101,47,6,0)
952^^2^2^3110430^
953"DATA",1130580001.101,47,6,1,0)
954Percentage of patients 18 - 75 years of age with
955"DATA",1130580001.101,47,6,2,0)
956diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
957"DATA",1130580001.101,47,7)
[1486]958NQF0061^^^^^^262^258
[1485]959"DATA",1130580001.101,48,0)
960MU EP NQF 0081^^
961"DATA",1130580001.101,48,1)
962Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
963"DATA",1130580001.101,48,5)
964Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
965"DATA",1130580001.101,48,6,0)
966^^3^3^3110430^
967"DATA",1130580001.101,48,6,1,0)
968Percentage of patients aged 18 years and older with a
969"DATA",1130580001.101,48,6,2,0)
970diagnosis of heart failure and LVSD (LVEF < 40%) who were
971"DATA",1130580001.101,48,6,3,0)
972prescribed ACE inhibitor or ARB therapy
973"DATA",1130580001.101,48,7)
974NQF0081^^^^
975"DATA",1130580001.101,49,0)
976MU EP NQF 0070^^
977"DATA",1130580001.101,49,1)
978Pneumonia Vaccination Status for Older Adults
979"DATA",1130580001.101,49,5)
980Pneumonia Vaccination Status for Older Adults
981"DATA",1130580001.101,49,6,0)
982^^2^2^3110430^
983"DATA",1130580001.101,49,6,1,0)
984Percentage of patients 65 years of age and older who have ever
985"DATA",1130580001.101,49,6,2,0)
986received a pneumococcal vaccine.
987"DATA",1130580001.101,49,7)
988NQF0070^^^^
989"DATA",1130580001.101,50,0)
990MU EP NQF 0031^^
991"DATA",1130580001.101,50,1)
992Breast Cancer Screening
993"DATA",1130580001.101,50,5)
994Breast Cancer Screening
995"DATA",1130580001.101,50,6,0)
996^^2^2^3110430^
997"DATA",1130580001.101,50,6,1,0)
998Percentage of women 40-69 years of age who had a
999"DATA",1130580001.101,50,6,2,0)
1000mammogram to screen for breast cancer
1001"DATA",1130580001.101,50,7)
1002NQF0031^^^^
1003"DATA",1130580001.101,51,0)
1004MU EP NQF 0034^^
1005"DATA",1130580001.101,51,1)
1006Colorectal Cancer Screening
1007"DATA",1130580001.101,51,5)
1008Colorectal Cancer Screening
1009"DATA",1130580001.101,51,6,0)
1010^^2^2^3110430^
1011"DATA",1130580001.101,51,6,1,0)
1012Percentage of adults 50-75 years of age who had appropriate screening for
1013"DATA",1130580001.101,51,6,2,0)
1014colorectal cancer.
1015"DATA",1130580001.101,51,7)
1016NQF0034^^^^
1017"DATA",1130580001.101,52,0)
1018MU EP NQF 0067^^
1019"DATA",1130580001.101,52,1)
1020Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1021"DATA",1130580001.101,52,5)
1022Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
1023"DATA",1130580001.101,52,6,0)
1024^^2^2^3110430^
1025"DATA",1130580001.101,52,6,1,0)
1026Percentage of patients aged 18 years and older with a
1027"DATA",1130580001.101,52,6,2,0)
1028diagnosis of CAD who were prescribed oral antiplatelet therapy.
1029"DATA",1130580001.101,52,7)
1030NQF0067^^^^
1031"DATA",1130580001.101,53,0)
1032MU EP NQF 0083^^
1033"DATA",1130580001.101,53,1)
1034Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1035"DATA",1130580001.101,53,5)
1036Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
1037"DATA",1130580001.101,53,6,0)
1038^^3^3^3110430^
1039"DATA",1130580001.101,53,6,1,0)
1040Percentage of patients aged 18 years and older with a
1041"DATA",1130580001.101,53,6,2,0)
1042diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
1043"DATA",1130580001.101,53,6,3,0)
1044prescribed beta-blocker therapy
1045"DATA",1130580001.101,53,7)
1046NQF0083^^^^
1047"DATA",1130580001.101,54,0)
1048MU EP NQF 0105^^
1049"DATA",1130580001.101,54,1)
1050Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1051"DATA",1130580001.101,54,5)
1052Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
1053"DATA",1130580001.101,54,6,0)
1054^^4^4^3110430^
1055"DATA",1130580001.101,54,6,1,0)
1056The percentage of patients 18 years of age and older
1057"DATA",1130580001.101,54,6,2,0)
1058who were diagnosed with a new episode of major depression, treated
1059"DATA",1130580001.101,54,6,3,0)
1060with antidepressant medication, and who remained on an
1061"DATA",1130580001.101,54,6,4,0)
1062antidepressant medication treatment.
1063"DATA",1130580001.101,54,7)
1064NQF0105^^^^
1065"DATA",1130580001.101,55,0)
1066MU EP NQF 0086^^
1067"DATA",1130580001.101,55,1)
1068Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1069"DATA",1130580001.101,55,5)
1070Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
1071"DATA",1130580001.101,55,6,0)
1072^^4^4^3110430^
1073"DATA",1130580001.101,55,6,1,0)
1074Percentage of patients aged 18 years and older with a
1075"DATA",1130580001.101,55,6,2,0)
1076diagnosis of POAG who have been seen for at least two office visits
1077"DATA",1130580001.101,55,6,3,0)
1078who have an optic nerve head evaluation during one or more office
1079"DATA",1130580001.101,55,6,4,0)
1080visits within 12 months.
1081"DATA",1130580001.101,55,7)
1082NQF0086^^^^
1083"DATA",1130580001.101,56,0)
1084MU EP NQF 0088^^
1085"DATA",1130580001.101,56,1)
1086Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1087"DATA",1130580001.101,56,5)
1088Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
1089"DATA",1130580001.101,56,6,0)
1090^^5^5^3110430^
1091"DATA",1130580001.101,56,6,1,0)
1092Percentage of patients aged 18 years and older with a
1093"DATA",1130580001.101,56,6,2,0)
1094diagnosis of diabetic retinopathy who had a dilated macular or fundus
1095"DATA",1130580001.101,56,6,3,0)
1096exam performed which included documentation of the level of severity
1097"DATA",1130580001.101,56,6,4,0)
1098of retinopathy and the presence or absence of macular edema during
1099"DATA",1130580001.101,56,6,5,0)
1100one or more office visits within 12 months.
1101"DATA",1130580001.101,56,7)
1102NQF0088^^^^
1103"DATA",1130580001.101,57,0)
1104MU EP NQF 0089^^
1105"DATA",1130580001.101,57,1)
1106Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1107"DATA",1130580001.101,57,5)
1108Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
1109"DATA",1130580001.101,57,6,0)
1110^^6^6^3110430^
1111"DATA",1130580001.101,57,6,1,0)
1112Percentage of patients aged 18 years and older with a
1113"DATA",1130580001.101,57,6,2,0)
1114diagnosis of diabetic retinopathy who had a dilated macular or fundus
1115"DATA",1130580001.101,57,6,3,0)
1116exam performed with documented communication to the physician who
1117"DATA",1130580001.101,57,6,4,0)
1118manages the ongoing care of the patient with diabetes mellitus
1119"DATA",1130580001.101,57,6,5,0)
1120regarding the findings of the macular or fundus exam at least once
1121"DATA",1130580001.101,57,6,6,0)
1122within 12 months.
1123"DATA",1130580001.101,57,7)
1124NQF0089^^^^
1125"DATA",1130580001.101,58,0)
1126MU EP NQF 0047^^
1127"DATA",1130580001.101,58,1)
1128Asthma Pharmacologic Therapy
1129"DATA",1130580001.101,58,5)
1130Asthma Pharmacologic Therapy
1131"DATA",1130580001.101,58,6,0)
1132^1130580001.111^4^4^3110430^^
1133"DATA",1130580001.101,58,6,1,0)
1134Percentage of patients aged 5 through 40 years with a
1135"DATA",1130580001.101,58,6,2,0)
1136diagnosis of mild, moderate, or severe persistent asthma who were
1137"DATA",1130580001.101,58,6,3,0)
1138prescribed either the preferred long-term control medication (inhaled
1139"DATA",1130580001.101,58,6,4,0)
1140corticosteroid) or an acceptable alternative treatment
1141"DATA",1130580001.101,58,7)
1142NQF0047^^^^
1143"DATA",1130580001.101,59,0)
1144MU EP NQF 0001^^
1145"DATA",1130580001.101,59,1)
1146Asthma Assessment
1147"DATA",1130580001.101,59,5)
1148Asthma Assessment
1149"DATA",1130580001.101,59,6,0)
1150^^5^5^3110430^
1151"DATA",1130580001.101,59,6,1,0)
1152Percentage of patients aged 5 through 40 years with a
1153"DATA",1130580001.101,59,6,2,0)
1154diagnosis of asthma and who have been seen for at least 2 office
1155"DATA",1130580001.101,59,6,3,0)
1156visits, who were evaluated during at least one office visit within 12
1157"DATA",1130580001.101,59,6,4,0)
1158months for the frequency (numeric) of daytime and nocturnal asthma
1159"DATA",1130580001.101,59,6,5,0)
1160symptoms.
1161"DATA",1130580001.101,59,7)
1162NQF0001^^^^
1163"DATA",1130580001.101,60,0)
1164MU EP NQF 0002^^
1165"DATA",1130580001.101,60,1)
1166Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
1167"DATA",1130580001.101,60,5)
1168Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
1169"DATA",1130580001.101,60,6,0)
1170^^4^4^3110430^
1171"DATA",1130580001.101,60,6,1,0)
1172Percentage of female patients aged 18 years and older
1173"DATA",1130580001.101,60,6,2,0)
1174with Stage IC through IIIC, ER or PR positive breast cancer who were
1175"DATA",1130580001.101,60,6,3,0)
1176prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
1177"DATA",1130580001.101,60,6,4,0)
1178reporting period.
1179"DATA",1130580001.101,60,7)
1180NQF0002^^^^
1181"DATA",1130580001.101,61,0)
1182MU EP NQF 0385^^
1183"DATA",1130580001.101,61,1)
1184Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1185"DATA",1130580001.101,61,5)
1186Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
1187"DATA",1130580001.101,61,6,0)
1188^^4^4^3110430^
1189"DATA",1130580001.101,61,6,1,0)
1190Percentage of patients aged 18 years and older with
1191"DATA",1130580001.101,61,6,2,0)
1192Stage IIIA through IIIC colon cancer who are referred for adjuvant
1193"DATA",1130580001.101,61,6,3,0)
1194chemotherapy, prescribed adjuvant chemotherapy, or have previously
1195"DATA",1130580001.101,61,6,4,0)
1196received adjuvant chemotherapy within the 12-month reporting period
1197"DATA",1130580001.101,61,7)
1198NQF0385^^^^
1199"DATA",1130580001.101,62,0)
1200MU EP NQF 0389^^
1201"DATA",1130580001.101,62,1)
1202Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1203"DATA",1130580001.101,62,5)
1204Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
1205"DATA",1130580001.101,62,6,0)
1206^^5^5^3110430^
1207"DATA",1130580001.101,62,6,1,0)
1208Percentage of patients, regardless of age, with a diagnosis of
1209"DATA",1130580001.101,62,6,2,0)
1210prostate cancer at low risk of recurrence receiving interstitial prostate
1211"DATA",1130580001.101,62,6,3,0)
1212brachytherapy, OR external beam radiotherapy to the prostate, OR radical
1213"DATA",1130580001.101,62,6,4,0)
1214prostatectomy, OR cryotherapy who did not have a bone scan performed at
1215"DATA",1130580001.101,62,6,5,0)
1216any time since diagnosis of prostate cancer.
1217"DATA",1130580001.101,62,7)
1218NQF0389^^^^
1219"DATA",1130580001.101,63,0)
1220MU EP NQF 0027^^
1221"DATA",1130580001.101,63,1)
1222Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
1223"DATA",1130580001.101,63,5)
1224Smoking and Tobacco Use Cessation
1225"DATA",1130580001.101,63,6,0)
1226^^5^5^3110430^
1227"DATA",1130580001.101,63,6,1,0)
1228Percentage of patients 18 years of age and older who were
1229"DATA",1130580001.101,63,6,2,0)
1230current smokers or tobacco users, who were seen by a practitioner during
1231"DATA",1130580001.101,63,6,3,0)
1232the measurement year and who received advice to quit smoking or tobacco
1233"DATA",1130580001.101,63,6,4,0)
1234use or whose practitioner recommended or discussed smoking or tobacco use
1235"DATA",1130580001.101,63,6,5,0)
1236cessation medications, methods or strategies
1237"DATA",1130580001.101,63,7)
1238NQF0027^^^^
1239"DATA",1130580001.101,64,0)
1240MU EP NQF 0055^^
1241"DATA",1130580001.101,64,1)
1242Diabetes: Eye Exam
1243"DATA",1130580001.101,64,5)
1244Diabetes: Eye Exam
1245"DATA",1130580001.101,64,6,0)
1246^^3^3^3110430^
1247"DATA",1130580001.101,64,6,1,0)
1248Percentage of patients 18 -75 years of age with diabetes (type 1
1249"DATA",1130580001.101,64,6,2,0)
1250or type 2) who had a retinal or dilated eye exam or a negative retinal
1251"DATA",1130580001.101,64,6,3,0)
1252exam (no evidence of retinopathy) by an eye care professional
1253"DATA",1130580001.101,64,7)
1254NQF0055^^^^
1255"DATA",1130580001.101,65,0)
1256MU EP NQF 0062^^
1257"DATA",1130580001.101,65,1)
1258Diabetes: Urine Screening
1259"DATA",1130580001.101,65,5)
1260Diabetes: Urine Screening
1261"DATA",1130580001.101,65,6,0)
1262^^3^3^3110430^
1263"DATA",1130580001.101,65,6,1,0)
1264Percentage of patients 18 - 75 years of age with diabetes (type 1
1265"DATA",1130580001.101,65,6,2,0)
1266or type 2) who had a nephropathy screening test or evidence of
1267"DATA",1130580001.101,65,6,3,0)
1268nephropathy.
1269"DATA",1130580001.101,65,7)
1270NQF0062^^^^
1271"DATA",1130580001.101,66,0)
1272MU EP NQF 0056^^
1273"DATA",1130580001.101,66,1)
1274Diabetes: Foot Exam
1275"DATA",1130580001.101,66,5)
1276Diabetes: Foot Exam
1277"DATA",1130580001.101,66,6,0)
1278^^3^3^3110430^
1279"DATA",1130580001.101,66,6,1,0)
1280The percentage of patients aged 18 - 75 years with diabetes
1281"DATA",1130580001.101,66,6,2,0)
1282(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1283"DATA",1130580001.101,66,6,3,0)
1284with monofilament, or pulse exam).
1285"DATA",1130580001.101,66,7)
1286NQF0056^^^^
1287"DATA",1130580001.101,67,0)
1288MU EP NQF 0074^^
1289"DATA",1130580001.101,67,1)
1290Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1291"DATA",1130580001.101,67,5)
1292Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1293"DATA",1130580001.101,67,6,0)
1294^^3^3^3110430^
1295"DATA",1130580001.101,67,6,1,0)
1296Percentage of patients aged 18 years and older with a
1297"DATA",1130580001.101,67,6,2,0)
1298diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1299"DATA",1130580001.101,67,6,3,0)
1300on current ACC/AHA guidelines).
1301"DATA",1130580001.101,67,7)
1302NQF0074^^^^
1303"DATA",1130580001.101,68,0)
1304MU EP NQF 0084^^
1305"DATA",1130580001.101,68,1)
1306Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1307"DATA",1130580001.101,68,5)
1308Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1309"DATA",1130580001.101,68,6,0)
1310^^3^3^3110430^
1311"DATA",1130580001.101,68,6,1,0)
1312Percentage of all patients aged 18 years and older with a
1313"DATA",1130580001.101,68,6,2,0)
1314diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1315"DATA",1130580001.101,68,6,3,0)
1316who were prescribed warfarin therapy.
1317"DATA",1130580001.101,68,7)
1318NQF0084^^^^
1319"DATA",1130580001.101,69,0)
1320MU EP NQF 0073^^
1321"DATA",1130580001.101,69,1)
1322Ischemic Vascular Disease (IVD): Blood Pressure Management
1323"DATA",1130580001.101,69,5)
1324Ischemic Vascular Disease (IVD): Blood Pressure Management
1325"DATA",1130580001.101,69,6,0)
1326^^11^11^3110430^
1327"DATA",1130580001.101,69,6,1,0)
1328Percentage of patients 18 years of age and older who
1329"DATA",1130580001.101,69,6,2,0)
1330were discharged alive for acute myocardial infarction (AMI), coronary
1331"DATA",1130580001.101,69,6,3,0)
1332artery bypass graft (CABG) or percutaneous transluminal coronary
1333"DATA",1130580001.101,69,6,4,0)
1334Percentage of patients 18 years of age and older who
1335"DATA",1130580001.101,69,6,5,0)
1336were discharged alive for acute myocardial infarction (AMI), coronary
1337"DATA",1130580001.101,69,6,6,0)
1338artery bypass graft (CABG) or percutaneous transluminal coronary
1339"DATA",1130580001.101,69,6,7,0)
1340angioplasty (PTCA) from January 1- November 1 of the year prior to
1341"DATA",1130580001.101,69,6,8,0)
1342the measurement year, or who had a diagnosis of ischemic vascular
1343"DATA",1130580001.101,69,6,9,0)
1344disease (IVD) during the measurement year and the year prior to the
1345"DATA",1130580001.101,69,6,10,0)
1346measurement year and whose recent blood pressure is in control
1347"DATA",1130580001.101,69,6,11,0)
1348(<140/90 mmHg).
1349"DATA",1130580001.101,69,7)
1350NQF0073^^^^
1351"DATA",1130580001.101,70,0)
1352MU EP NQF 0068^^
1353"DATA",1130580001.101,70,1)
1354Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1355"DATA",1130580001.101,70,5)
1356 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1357"DATA",1130580001.101,70,6,0)
1358^^8^8^3110430^
1359"DATA",1130580001.101,70,6,1,0)
1360 Percentage of patients 18 years of age and older who were
1361"DATA",1130580001.101,70,6,2,0)
1362discharged alive for acute myocardial infarction (AMI), coronary artery
1363"DATA",1130580001.101,70,6,3,0)
1364bypass graft (CABG) or percutaneous transluminal coronary
1365"DATA",1130580001.101,70,6,4,0)
1366angioplasty (PTCA) from January 1-November 1 of the year prior to the
1367"DATA",1130580001.101,70,6,5,0)
1368measurement year, or who had a diagnosis of ischemic vascular
1369"DATA",1130580001.101,70,6,6,0)
1370disease (IVD) during the measurement year and the year prior to the
1371"DATA",1130580001.101,70,6,7,0)
1372measurement year and who had documentation of use of aspirin or
1373"DATA",1130580001.101,70,6,8,0)
1374another antithrombotic during the measurement year
1375"DATA",1130580001.101,70,7)
1376NQF0068^^^^
1377"DATA",1130580001.101,71,0)
1378MU EP NQF 0004^^
1379"DATA",1130580001.101,71,1)
1380 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1381"DATA",1130580001.101,71,5)
1382Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1383"DATA",1130580001.101,71,6,0)
1384^^6^6^3110430^
1385"DATA",1130580001.101,71,6,1,0)
1386The percentage of adolescent and adult patients with a new
1387"DATA",1130580001.101,71,6,2,0)
1388episode of alcohol and other drug (AOD) dependence who initiate treatment
1389"DATA",1130580001.101,71,6,3,0)
1390through an inpatient AOD admission, outpatient visit, intensive
1391"DATA",1130580001.101,71,6,4,0)
1392outpatient encounter or partial hospitalization within 14 days of the
1393"DATA",1130580001.101,71,6,5,0)
1394diagnosis and who initiated treatment and who had two or more additional
1395"DATA",1130580001.101,71,6,6,0)
1396services with an AOD diagnosis within 30 days of the initiation visit.
1397"DATA",1130580001.101,71,7)
1398NQF0004^^^^
1399"DATA",1130580001.101,72,0)
1400MU EP NQF 0012^^
1401"DATA",1130580001.101,72,1)
1402Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1403"DATA",1130580001.101,72,5)
1404Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1405"DATA",1130580001.101,72,6,0)
1406^^3^3^3110430^
1407"DATA",1130580001.101,72,6,1,0)
1408Percentage of patients, regardless of age, who gave birth during
1409"DATA",1130580001.101,72,6,2,0)
1410a 12-month period who were screened for HIV infection during the first or
1411"DATA",1130580001.101,72,6,3,0)
1412second prenatal care visit.
1413"DATA",1130580001.101,72,7)
1414NQF0012^^^^
1415"DATA",1130580001.101,73,0)
1416MU EP NQF 0014^^
1417"DATA",1130580001.101,73,1)
1418Prenatal Care: Anti-D Immune Globulin
1419"DATA",1130580001.101,73,5)
1420Prenatal Care: Anti-D Immune Globulin
1421"DATA",1130580001.101,73,6,0)
1422^^3^3^3110430^
1423"DATA",1130580001.101,73,6,1,0)
1424Percentage of D (Rh) negative, unsensitized patients, regardless
1425"DATA",1130580001.101,73,6,2,0)
1426of age, who gave birth during a 12-month period who received anti-D
1427"DATA",1130580001.101,73,6,3,0)
1428immune globulin at 26-30 weeks gestation.
1429"DATA",1130580001.101,73,7)
1430NQD0014^^^^
1431"DATA",1130580001.101,74,0)
1432MU EP NQF 0018^^
1433"DATA",1130580001.101,74,1)
1434Controlling High Blood Pressure
1435"DATA",1130580001.101,74,5)
1436Controlling High Blood Pressure
1437"DATA",1130580001.101,74,6,0)
1438^^3^3^3110430^
1439"DATA",1130580001.101,74,6,1,0)
1440The percentage of patients 18-85 years of age who had a
1441"DATA",1130580001.101,74,6,2,0)
1442diagnosis of hypertension and whose BP was adequately controlled during
1443"DATA",1130580001.101,74,6,3,0)
1444the measurement year
1445"DATA",1130580001.101,74,7)
1446NQF0018^^^^
1447"DATA",1130580001.101,75,0)
1448MU EP NQF 0032^^
1449"DATA",1130580001.101,75,1)
1450Cervical Cancer Screening
1451"DATA",1130580001.101,75,5)
1452Cervical Cancer Screening
1453"DATA",1130580001.101,75,6,0)
1454^^2^2^3110430^
1455"DATA",1130580001.101,75,6,1,0)
1456Percentage of women 21-64 years of age, who received one or
1457"DATA",1130580001.101,75,6,2,0)
1458more Pap tests to screen for cervical cancer
1459"DATA",1130580001.101,75,7)
1460NQF0032^^^^
1461"DATA",1130580001.101,76,0)
1462MU EP NQF 0033^^
1463"DATA",1130580001.101,76,1)
1464Chlamydia Screening for Women
1465"DATA",1130580001.101,76,5)
1466Chlamydia Screening for Women
1467"DATA",1130580001.101,76,6,0)
1468^^3^3^3110430^
1469"DATA",1130580001.101,76,6,1,0)
1470Percentage of women 15- 24 years of age who were identified as sexually
1471"DATA",1130580001.101,76,6,2,0)
1472active and who had at least one test for chlamydia during the measurement
1473"DATA",1130580001.101,76,6,3,0)
1474year.
1475"DATA",1130580001.101,76,7)
1476NQF0033^^^^
1477"DATA",1130580001.101,77,0)
1478MU EP NQF 0036^^
1479"DATA",1130580001.101,77,1)
1480Use of Appropriate Medications for Asthma
1481"DATA",1130580001.101,77,5)
1482Use of Appropriate Medications for Asthma
1483"DATA",1130580001.101,77,6,0)
1484^^4^4^3110430^
1485"DATA",1130580001.101,77,6,1,0)
1486Percentage of patients 5 - 50 years of age who were identified as having
1487"DATA",1130580001.101,77,6,2,0)
1488persistent asthma and were appropriately prescribed medication during the
1489"DATA",1130580001.101,77,6,3,0)
1490measurement year. Report three age stratifications (5-11 years, 12-50
1491"DATA",1130580001.101,77,6,4,0)
1492years, and total).
1493"DATA",1130580001.101,77,7)
1494NQF0036^^^^
1495"DATA",1130580001.101,78,0)
1496MU EP NQF 0052^^
1497"DATA",1130580001.101,78,1)
1498Low Back Pain: Use of Imaging Studies
1499"DATA",1130580001.101,78,5)
1500Low Back Pain: Use of Imaging Studies
1501"DATA",1130580001.101,78,6,0)
1502^1130580001.111^3^3^3110430^^
1503"DATA",1130580001.101,78,6,1,0)
1504Percentage of patients with a primary diagnosis of low back pain
1505"DATA",1130580001.101,78,6,2,0)
1506who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1507"DATA",1130580001.101,78,6,3,0)
1508days of diagnosis.
1509"DATA",1130580001.101,78,7)
1510NQF0052^^^^
1511"DATA",1130580001.101,79,0)
1512MU EP NQF 0075^^
1513"DATA",1130580001.101,79,1)
1514Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1515"DATA",1130580001.101,79,5)
1516Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1517"DATA",1130580001.101,79,6,0)
1518^^7^7^3110430^
1519"DATA",1130580001.101,79,6,1,0)
1520Percentage of patients 18 years of age and older who were discharged alive
1521"DATA",1130580001.101,79,6,2,0)
1522for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1523"DATA",1130580001.101,79,6,3,0)
1524or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1525"DATA",1130580001.101,79,6,4,0)
1526of the year prior to the measurement year, or who had a diagnosis of
1527"DATA",1130580001.101,79,6,5,0)
1528ischemic vascular disease (IVD) during the measurement year and the year
1529"DATA",1130580001.101,79,6,6,0)
1530prior to the measurement year and who had a complete lipid profile
1531"DATA",1130580001.101,79,6,7,0)
1532performed during the measurement year and whose LDL-C<100 mg/dL
1533"DATA",1130580001.101,79,7)
1534NQF0075^^^^
1535"DATA",1130580001.101,80,0)
1536MU EP NQF 0575^^
1537"DATA",1130580001.101,80,1)
1538Diabetes: Hemoglobin A1c Control (<8.0%)
1539"DATA",1130580001.101,80,5)
1540Diabetes: Hemoglobin A1c Control (<8.0%)
1541"DATA",1130580001.101,80,6,0)
1542^^2^2^3110430^
1543"DATA",1130580001.101,80,6,1,0)
1544The percentage of patients 18-75 years of age with diabetes
1545"DATA",1130580001.101,80,6,2,0)
1546(type 1 or type 2) who had hemoglobin A1c <8.0%
1547"DATA",1130580001.101,80,7)
1548NQF0575^^^^
1549"DATA",1130580001.101,81,0)
1550MU EP NQF 0028B^^
1551"DATA",1130580001.101,81,1)
1552NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1553"DATA",1130580001.101,81,5)
1554NQF0028B Tobacco Use Assessment and Cessation Intervention
1555"DATA",1130580001.101,81,6,0)
1556^1130580001.111^7^7^3110625^^^^
1557"DATA",1130580001.101,81,6,1,0)
1558 Percentage of patients aged 18 years and
1559"DATA",1130580001.101,81,6,2,0)
1560older who have been seen for at least 2 office visits who
1561"DATA",1130580001.101,81,6,3,0)
1562were queried about tobacco use one or more times within
1563"DATA",1130580001.101,81,6,4,0)
156424 months b. Percentage of patients aged 18 years and
1565"DATA",1130580001.101,81,6,5,0)
1566older identified as tobacco users within the past 24
1567"DATA",1130580001.101,81,6,6,0)
1568months and have been seen for at least 2 office visits,
1569"DATA",1130580001.101,81,6,7,0)
1570who received cessation intervention.
1571"DATA",1130580001.101,81,7)
1572NQF0028B^^^^^^154^160
1573"DATA",1130580001.101,82,0)
1574MU EP 0028B^^
1575"DATA",1130580001.101,82,7)
1576^^^^
1577"DATA",1130580001.101,83,0)
1578NQF0038 NUM1 DPT^^
1579"DATA",1130580001.101,83,5)
1580NQF0038 NUM1 DPT
1581"DATA",1130580001.101,83,7)
1582NQF0038 NUM1 DPT^^^^
1583"DATA",1130580001.101,84,0)
1584NQF0038 NUM2 IPV^^
1585"DATA",1130580001.101,84,5)
1586NQF0038 NUM2 IPV
1587"DATA",1130580001.101,84,7)
1588NQF0038 NUM2 IPV^^^^
1589"DATA",1130580001.101,85,0)
1590NQF0038 NUM3 MMR^^
1591"DATA",1130580001.101,85,5)
1592NQF0038 NUM3 MMR
1593"DATA",1130580001.101,85,7)
1594NQF0038 NUM3 MMR^^^^
1595"DATA",1130580001.101,86,0)
1596NQF0038 NUM4 HiB^^
1597"DATA",1130580001.101,86,5)
1598NQF0038 NUM4 HiB
1599"DATA",1130580001.101,86,7)
1600NQF0038 NUM4 HiB^^^^
1601"DATA",1130580001.101,87,0)
1602NQF0038 NUM5 HEP B^^
1603"DATA",1130580001.101,87,5)
1604NQF0038 NUM5 HEP B
1605"DATA",1130580001.101,87,7)
1606NQF0038 NUM5 HEP B^^^^
1607"DATA",1130580001.101,88,0)
1608NQF0038 NUM6 VZV^^
1609"DATA",1130580001.101,88,5)
1610NQF0038 NUM6 VZV
1611"DATA",1130580001.101,88,7)
1612NQF0038 NUM6 VZV^^^^
1613"DATA",1130580001.101,89,0)
1614NQF0038 NUM7 PCV^^
1615"DATA",1130580001.101,89,5)
1616NQF0038 NUM7 PCV
1617"DATA",1130580001.101,89,7)
1618NQF0038 NUM7 PCV^^^^
1619"DATA",1130580001.101,90,0)
1620NQF0038 NUM8 HEP A^^
1621"DATA",1130580001.101,90,5)
1622NQF0038 NUM8 HEP A
1623"DATA",1130580001.101,90,7)
1624NQF0038 NUM8 HEP A^^^^
1625"DATA",1130580001.101,91,0)
1626NQF0038 NUM9^^
1627"DATA",1130580001.101,91,5)
1628NQF0038 NUM9
1629"DATA",1130580001.101,91,7)
1630NQF0038 NUM9^^^^
1631"DATA",1130580001.101,92,0)
1632NQF0038 NUM10^^
1633"DATA",1130580001.101,92,5)
1634NQF0038 NUM10
1635"DATA",1130580001.101,92,7)
1636NQF0038 NUM10^^^^
1637"DATA",1130580001.101,93,0)
1638NQF0038 NUM11 COMBO5^^
1639"DATA",1130580001.101,93,5)
1640NQF0038 NUM11 COMBO5
1641"DATA",1130580001.101,93,7)
1642NQF0038 NUM11 COMBO5^^^^
1643"DATA",1130580001.101,94,0)
1644NQF0038 NUM12 COMBO6^^
1645"DATA",1130580001.101,94,5)
1646NQF0038 NUM12 COMBO6
1647"DATA",1130580001.101,94,7)
1648NQF0038 NUM12 COMBO6^^^^
1649"DATA",1130580001.101,95,0)
1650MU 2011 INP ADV DIRECTIVES^^
1651"DATA",1130580001.101,95,5)
1652Advance Directives
1653"DATA",1130580001.101,95,7)
1654^^^^
1655"DATA",1130580001.101,96,0)
1656MU 2011 INP CPOE^^
1657"DATA",1130580001.101,96,5)
1658CPOE for Medications
1659"DATA",1130580001.101,96,7)
1660^^^^
1661"DATA",1130580001.101,97,0)
1662MU 2011 INP MED RECON^^
1663"DATA",1130580001.101,97,5)
1664Medication Reconcilliation
1665"DATA",1130580001.101,97,7)
1666^^^^
1667"DATA",1130580001.101,98,0)
1668MU 2011 INP PROBLEM LIST^^
1669"DATA",1130580001.101,98,5)
1670Problem List
1671"DATA",1130580001.101,98,7)
1672^^^^
1673"DATA",1130580001.101,99,0)
1674MU 2011 INP VITAL SIGNS^^
1675"DATA",1130580001.101,99,5)
1676Record Vital Signs
1677"DATA",1130580001.101,99,7)
1678^^^^
1679"DATA",1130580001.101,100,0)
1680MU 2011 INP SMOKING STATUS^^
1681"DATA",1130580001.101,100,5)
1682Smoking Status
1683"DATA",1130580001.101,100,7)
1684^^^^
1685"DATA",1130580001.101,101,0)
1686MU 2011 INP MED LIST^^
1687"DATA",1130580001.101,101,5)
1688Active Medication List
1689"DATA",1130580001.101,101,7)
1690^^^^
1691"DATA",1130580001.101,102,0)
1692MU 2011 INP ALLERGY LIST^^
1693"DATA",1130580001.101,102,5)
1694Medication Allergy List
1695"DATA",1130580001.101,102,7)
1696^^^^
1697"DATA",1130580001.101,103,0)
1698MU 2011 INP DEMOGRAPHICS^^
1699"DATA",1130580001.101,103,5)
1700Record Demographics
1701"DATA",1130580001.101,103,7)
1702^^^^
1703"FIA",1130580001.101)
1704C0Q QUALITY MEASURE
1705"FIA",1130580001.101,0)
1706^C0Q(101,
1707"FIA",1130580001.101,0,0)
17081130580001.101I
1709"FIA",1130580001.101,0,1)
1710y^y^f^^y^^y^o^n
1711"FIA",1130580001.101,0,10)
1712
1713"FIA",1130580001.101,0,11)
1714
1715"FIA",1130580001.101,0,"RLRO")
1716
1717"FIA",1130580001.101,0,"VR")
17181.0^C0Q
1719"FIA",1130580001.101,1130580001.101)
17200
1721"FIA",1130580001.101,1130580001.111)
17220
[1489]1723"FRV1",1130580001.101,"23,7",7)
1724MU ED-1 NUMER RS
1725"FRV1",1130580001.101,"23,7",7,"F")
1726;PXRM(810.4,
1727"FRV1",1130580001.101,"23,7",8)
1728MU ED-1 DENOM RS
1729"FRV1",1130580001.101,"23,7",8,"F")
1730;PXRM(810.4,
1731"FRV1",1130580001.101,"24,7",7)
1732MU ED-2 NUMER RS
1733"FRV1",1130580001.101,"24,7",7,"F")
1734;PXRM(810.4,
1735"FRV1",1130580001.101,"24,7",8)
1736MU ED-2 DENOM RS
1737"FRV1",1130580001.101,"24,7",8,"F")
1738;PXRM(810.4,
[1490]1739"FRV1",1130580001.101,"25,7",7)
1740MU STK-2 NUMER RS
1741"FRV1",1130580001.101,"25,7",7,"F")
1742;PXRM(810.4,
1743"FRV1",1130580001.101,"25,7",8)
1744MU STK-2 DENOM RS
1745"FRV1",1130580001.101,"25,7",8,"F")
1746;PXRM(810.4,
1747"FRV1",1130580001.101,"26,7",7)
1748MU STK-3 NUMER RS
1749"FRV1",1130580001.101,"26,7",7,"F")
1750;PXRM(810.4,
1751"FRV1",1130580001.101,"26,7",8)
1752MU STK-3 DENOM RS
1753"FRV1",1130580001.101,"26,7",8,"F")
1754;PXRM(810.4,
1755"FRV1",1130580001.101,"27,7",7)
1756MU STK-4 NUMER RS
1757"FRV1",1130580001.101,"27,7",7,"F")
1758;PXRM(810.4,
1759"FRV1",1130580001.101,"27,7",8)
1760MU STK-4 DENOM RS
1761"FRV1",1130580001.101,"27,7",8,"F")
1762;PXRM(810.4,
1763"FRV1",1130580001.101,"28,7",7)
1764MU STK-5 NUMER RS
1765"FRV1",1130580001.101,"28,7",7,"F")
1766;PXRM(810.4,
1767"FRV1",1130580001.101,"28,7",8)
1768MU STK-5 DENOM RS
1769"FRV1",1130580001.101,"28,7",8,"F")
1770;PXRM(810.4,
1771"FRV1",1130580001.101,"29,7",7)
1772MU STK-6 NUMER RS
1773"FRV1",1130580001.101,"29,7",7,"F")
1774;PXRM(810.4,
1775"FRV1",1130580001.101,"29,7",8)
1776MU STK-6 DENOM RS
1777"FRV1",1130580001.101,"29,7",8,"F")
1778;PXRM(810.4,
1779"FRV1",1130580001.101,"30,7",7)
1780MU STK-8 NUMER RS
1781"FRV1",1130580001.101,"30,7",7,"F")
1782;PXRM(810.4,
1783"FRV1",1130580001.101,"30,7",8)
1784MU STK-8 DENOM RS
1785"FRV1",1130580001.101,"30,7",8,"F")
1786;PXRM(810.4,
1787"FRV1",1130580001.101,"31,7",7)
1788MU STK-10 NUMER RS
1789"FRV1",1130580001.101,"31,7",7,"F")
1790;PXRM(810.4,
1791"FRV1",1130580001.101,"31,7",8)
1792MU STK-10 DENOM RS
1793"FRV1",1130580001.101,"31,7",8,"F")
1794;PXRM(810.4,
[1485]1795"FRV1",1130580001.101,"40,7",7)
1796MU NQF0013 HTN NUMER2 RS
1797"FRV1",1130580001.101,"40,7",7,"F")
1798;PXRM(810.4,
1799"FRV1",1130580001.101,"40,7",8)
1800MU NQF0013 HTN DENOM2 RS
1801"FRV1",1130580001.101,"40,7",8,"F")
1802;PXRM(810.4,
1803"FRV1",1130580001.101,"41,7",7)
1804MU NQF0028A TOBACCO SCREEN NUM RS
1805"FRV1",1130580001.101,"41,7",7,"F")
1806;PXRM(810.4,
1807"FRV1",1130580001.101,"41,7",8)
1808MU NQF0028B TOBACCO INTERV DENOM RS
1809"FRV1",1130580001.101,"41,7",8,"F")
1810;PXRM(810.4,
1811"FRV1",1130580001.101,"42,7",7)
1812MU NQF0041 FLU RS
1813"FRV1",1130580001.101,"42,7",7,"F")
1814;PXRM(810.4,
1815"FRV1",1130580001.101,"42,7",8)
1816MU NQF0041 FLU DENOM RS
1817"FRV1",1130580001.101,"42,7",8,"F")
1818;PXRM(810.4,
1819"FRV1",1130580001.101,"43,7",7)
1820MU NQF0024 BMI 2-17YR NUM RS
1821"FRV1",1130580001.101,"43,7",7,"F")
1822;PXRM(810.4,
1823"FRV1",1130580001.101,"43,7",8)
1824MU NQF0024 BMI 2-17YRS DEM RS
1825"FRV1",1130580001.101,"43,7",8,"F")
1826;PXRM(810.4,
[1486]1827"FRV1",1130580001.101,"45,7",7)
1828MU NQF0059 HBA1C NUM RS
1829"FRV1",1130580001.101,"45,7",7,"F")
1830;PXRM(810.4,
1831"FRV1",1130580001.101,"45,7",8)
1832MU NQF0059 DM DENOM-ALL RS
1833"FRV1",1130580001.101,"45,7",8,"F")
1834;PXRM(810.4,
1835"FRV1",1130580001.101,"46,7",7)
1836MU NQF0064 NUM LDL RS
1837"FRV1",1130580001.101,"46,7",7,"F")
1838;PXRM(810.4,
1839"FRV1",1130580001.101,"46,7",8)
1840MU NQF0059 DM DENOM-ALL RS
1841"FRV1",1130580001.101,"46,7",8,"F")
1842;PXRM(810.4,
1843"FRV1",1130580001.101,"47,7",7)
1844MU NQF0061 NUM DM BP<140/90 RS
1845"FRV1",1130580001.101,"47,7",7,"F")
1846;PXRM(810.4,
1847"FRV1",1130580001.101,"47,7",8)
1848MU NQF0059 DM DENOM-ALL RS
1849"FRV1",1130580001.101,"47,7",8,"F")
1850;PXRM(810.4,
[1485]1851"FRV1",1130580001.101,"81,7",7)
1852MU NQF0028B TOBACCO INTERV NUM2 RS
1853"FRV1",1130580001.101,"81,7",7,"F")
1854;PXRM(810.4,
1855"FRV1",1130580001.101,"81,7",8)
1856MU NQF0028B TOBACCO INTERV DENOM RS
1857"FRV1",1130580001.101,"81,7",8,"F")
1858;PXRM(810.4,
[1489]1859"FRV1K",1130580001.101,"23,7",7)
1860B
1861"FRV1K",1130580001.101,"23,7",7,1)
1862MU ED-1 NUMER RS
1863"FRV1K",1130580001.101,"23,7",8)
1864B
1865"FRV1K",1130580001.101,"23,7",8,1)
1866MU ED-1 DENOM RS
1867"FRV1K",1130580001.101,"24,7",7)
1868B
1869"FRV1K",1130580001.101,"24,7",7,1)
1870MU ED-2 NUMER RS
1871"FRV1K",1130580001.101,"24,7",8)
1872B
1873"FRV1K",1130580001.101,"24,7",8,1)
1874MU ED-2 DENOM RS
[1490]1875"FRV1K",1130580001.101,"25,7",7)
1876B
1877"FRV1K",1130580001.101,"25,7",7,1)
1878MU STK-2 NUMER RS
1879"FRV1K",1130580001.101,"25,7",8)
1880B
1881"FRV1K",1130580001.101,"25,7",8,1)
1882MU STK-2 DENOM RS
1883"FRV1K",1130580001.101,"26,7",7)
1884B
1885"FRV1K",1130580001.101,"26,7",7,1)
1886MU STK-3 NUMER RS
1887"FRV1K",1130580001.101,"26,7",8)
1888B
1889"FRV1K",1130580001.101,"26,7",8,1)
1890MU STK-3 DENOM RS
1891"FRV1K",1130580001.101,"27,7",7)
1892B
1893"FRV1K",1130580001.101,"27,7",7,1)
1894MU STK-4 NUMER RS
1895"FRV1K",1130580001.101,"27,7",8)
1896B
1897"FRV1K",1130580001.101,"27,7",8,1)
1898MU STK-4 DENOM RS
1899"FRV1K",1130580001.101,"28,7",7)
1900B
1901"FRV1K",1130580001.101,"28,7",7,1)
1902MU STK-5 NUMER RS
1903"FRV1K",1130580001.101,"28,7",8)
1904B
1905"FRV1K",1130580001.101,"28,7",8,1)
1906MU STK-5 DENOM RS
1907"FRV1K",1130580001.101,"29,7",7)
1908B
1909"FRV1K",1130580001.101,"29,7",7,1)
1910MU STK-6 NUMER RS
1911"FRV1K",1130580001.101,"29,7",8)
1912B
1913"FRV1K",1130580001.101,"29,7",8,1)
1914MU STK-6 DENOM RS
1915"FRV1K",1130580001.101,"30,7",7)
1916B
1917"FRV1K",1130580001.101,"30,7",7,1)
1918MU STK-8 NUMER RS
1919"FRV1K",1130580001.101,"30,7",8)
1920B
1921"FRV1K",1130580001.101,"30,7",8,1)
1922MU STK-8 DENOM RS
1923"FRV1K",1130580001.101,"31,7",7)
1924B
1925"FRV1K",1130580001.101,"31,7",7,1)
1926MU STK-10 NUMER RS
1927"FRV1K",1130580001.101,"31,7",8)
1928B
1929"FRV1K",1130580001.101,"31,7",8,1)
1930MU STK-10 DENOM RS
[1485]1931"FRV1K",1130580001.101,"40,7",7)
1932B
1933"FRV1K",1130580001.101,"40,7",7,1)
1934MU NQF0013 HTN NUMER2 RS
1935"FRV1K",1130580001.101,"40,7",8)
1936B
1937"FRV1K",1130580001.101,"40,7",8,1)
1938MU NQF0013 HTN DENOM2 RS
1939"FRV1K",1130580001.101,"41,7",7)
1940B
1941"FRV1K",1130580001.101,"41,7",7,1)
1942MU NQF0028A TOBACCO SCREEN NUM RS
1943"FRV1K",1130580001.101,"41,7",8)
1944B
1945"FRV1K",1130580001.101,"41,7",8,1)
1946MU NQF0028B TOBACCO INTERV DENOM RS
1947"FRV1K",1130580001.101,"42,7",7)
1948B
1949"FRV1K",1130580001.101,"42,7",7,1)
1950MU NQF0041 FLU RS
1951"FRV1K",1130580001.101,"42,7",8)
1952B
1953"FRV1K",1130580001.101,"42,7",8,1)
1954MU NQF0041 FLU DENOM RS
1955"FRV1K",1130580001.101,"43,7",7)
1956B
1957"FRV1K",1130580001.101,"43,7",7,1)
1958MU NQF0024 BMI 2-17YR NUM RS
1959"FRV1K",1130580001.101,"43,7",8)
1960B
1961"FRV1K",1130580001.101,"43,7",8,1)
1962MU NQF0024 BMI 2-17YRS DEM RS
[1486]1963"FRV1K",1130580001.101,"45,7",7)
1964B
1965"FRV1K",1130580001.101,"45,7",7,1)
1966MU NQF0059 HBA1C NUM RS
1967"FRV1K",1130580001.101,"45,7",8)
1968B
1969"FRV1K",1130580001.101,"45,7",8,1)
1970MU NQF0059 DM DENOM-ALL RS
1971"FRV1K",1130580001.101,"46,7",7)
1972B
1973"FRV1K",1130580001.101,"46,7",7,1)
1974MU NQF0064 NUM LDL RS
1975"FRV1K",1130580001.101,"46,7",8)
1976B
1977"FRV1K",1130580001.101,"46,7",8,1)
1978MU NQF0059 DM DENOM-ALL RS
1979"FRV1K",1130580001.101,"47,7",7)
1980B
1981"FRV1K",1130580001.101,"47,7",7,1)
1982MU NQF0061 NUM DM BP<140/90 RS
1983"FRV1K",1130580001.101,"47,7",8)
1984B
1985"FRV1K",1130580001.101,"47,7",8,1)
1986MU NQF0059 DM DENOM-ALL RS
[1485]1987"FRV1K",1130580001.101,"81,7",7)
1988B
1989"FRV1K",1130580001.101,"81,7",7,1)
1990MU NQF0028B TOBACCO INTERV NUM2 RS
1991"FRV1K",1130580001.101,"81,7",8)
1992B
1993"FRV1K",1130580001.101,"81,7",8,1)
1994MU NQF0028B TOBACCO INTERV DENOM RS
1995"IX",1130580001.101,1130580001.101,"MU",0)
19961130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
1997"IX",1130580001.101,1130580001.101,"MU",1)
1998S ^C0Q(101,"MU",$E(X,1,30),DA)=""
1999"IX",1130580001.101,1130580001.101,"MU",2)
2000K ^C0Q(101,"MU",$E(X,1,30),DA)
2001"IX",1130580001.101,1130580001.101,"MU",2.5)
2002K ^C0Q(101,"MU")
2003"IX",1130580001.101,1130580001.101,"MU",11.1,0)
2004^.114IA^1^1
2005"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
20061^F^1130580001.101^.3^30^1^F
2007"MBREQ")
20080
2009"PGL",1130580001.101,0,2,1)
2010NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2011"PGL",1130580001.101,0,3,2)
2012DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2013"PGL",1130580001.101,7,2,1.1)
2014ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2015"PGL",1130580001.101,7,3,2.1)
2016ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2017"PGL",1130580001.101,7,4,1.5)
2018NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2019"PGL",1130580001.101,7,5,1.51)
2020ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2021"PGL",1130580001.101,7,7,1.2)
[1486]2022NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
[1485]2023"PGL",1130580001.101,7,8,2.2)
[1486]2024DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
[1485]2025"PKG",215,-1)
20261^1
2027"PKG",215,0)
2028QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
2029"PKG",215,20,0)
2030^9.402P^^
2031"PKG",215,22,0)
2032^9.49I^1^1
2033"PKG",215,22,1,0)
20341.0^3120713^3120702^8
2035"PKG",215,22,1,"PAH",1,0)
[1490]20363^3120718
[1485]2037"PKG",215,22,1,"PAH",1,1,0)
[1490]2038^^5^5^3120718
[1485]2039"PKG",215,22,1,"PAH",1,1,1,0)
2040Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
2041"PKG",215,22,1,"PAH",1,1,2,0)
20422.0.
2043"PKG",215,22,1,"PAH",1,1,3,0)
2044
2045"PKG",215,22,1,"PAH",1,1,4,0)
2046Contains updated C0Q QUALITY MEASURES file containing the appropriate
2047"PKG",215,22,1,"PAH",1,1,5,0)
2048rule sets to use after each measure.
2049"QUES","XPF1",0)
2050Y
2051"QUES","XPF1","??")
2052^D REP^XPDH
2053"QUES","XPF1","A")
2054Shall I write over your |FLAG| File
2055"QUES","XPF1","B")
2056YES
2057"QUES","XPF1","M")
2058D XPF1^XPDIQ
2059"QUES","XPF2",0)
2060Y
2061"QUES","XPF2","??")
2062^D DTA^XPDH
2063"QUES","XPF2","A")
2064Want my data |FLAG| yours
2065"QUES","XPF2","B")
2066YES
2067"QUES","XPF2","M")
2068D XPF2^XPDIQ
2069"QUES","XPI1",0)
2070YO
2071"QUES","XPI1","??")
2072^D INHIBIT^XPDH
2073"QUES","XPI1","A")
2074Want KIDS to INHIBIT LOGONs during the install
2075"QUES","XPI1","B")
2076NO
2077"QUES","XPI1","M")
2078D XPI1^XPDIQ
2079"QUES","XPM1",0)
2080PO^VA(200,:EM
2081"QUES","XPM1","??")
2082^D MG^XPDH
2083"QUES","XPM1","A")
2084Enter the Coordinator for Mail Group '|FLAG|'
2085"QUES","XPM1","B")
2086
2087"QUES","XPM1","M")
2088D XPM1^XPDIQ
2089"QUES","XPO1",0)
2090Y
2091"QUES","XPO1","??")
2092^D MENU^XPDH
2093"QUES","XPO1","A")
2094Want KIDS to Rebuild Menu Trees Upon Completion of Install
2095"QUES","XPO1","B")
2096NO
2097"QUES","XPO1","M")
2098D XPO1^XPDIQ
2099"QUES","XPZ1",0)
2100Y
2101"QUES","XPZ1","??")
2102^D OPT^XPDH
2103"QUES","XPZ1","A")
2104Want to DISABLE Scheduled Options, Menu Options, and Protocols
2105"QUES","XPZ1","B")
2106NO
2107"QUES","XPZ1","M")
2108D XPZ1^XPDIQ
2109"QUES","XPZ2",0)
2110Y
2111"QUES","XPZ2","??")
2112^D RTN^XPDH
2113"QUES","XPZ2","A")
2114Want to MOVE routines to other CPUs
2115"QUES","XPZ2","B")
2116NO
2117"QUES","XPZ2","M")
2118D XPZ2^XPDIQ
2119"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
2120
2121"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
2122@
2123"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
2124@
2125"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
2126@
2127"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
2128@
2129"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
2130@
2131"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
2132@
2133"VER")
21348.0^22.0
2135"^DD",1130580001.101,1130580001.101,0)
2136FIELD^^2.2^17
2137"^DD",1130580001.101,1130580001.101,0,"DDA")
2138N
2139"^DD",1130580001.101,1130580001.101,0,"DT")
[1486]21403120716
[1485]2141"^DD",1130580001.101,1130580001.101,0,"ID",.7)
2142W:$D(^(5)) " ",$P(^(5),U,1)
2143"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
2144
2145"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
2146
2147"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
2148
2149"^DD",1130580001.101,1130580001.101,0,"VRPK")
2150QUALITY MEASURES
2151"^DD",1130580001.101,1130580001.101,.01,0)
2152NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
2153"^DD",1130580001.101,1130580001.101,.01,.1)
2154MEASURE NAME
2155"^DD",1130580001.101,1130580001.101,.01,1,0)
2156^.1
2157"^DD",1130580001.101,1130580001.101,.01,1,1,0)
21581130580001.101^B
2159"^DD",1130580001.101,1130580001.101,.01,1,1,1)
2160S ^C0Q(101,"B",$E(X,1,30),DA)=""
2161"^DD",1130580001.101,1130580001.101,.01,1,1,2)
2162K ^C0Q(101,"B",$E(X,1,30),DA)
2163"^DD",1130580001.101,1130580001.101,.01,3)
2164Answer must be 1-30 characters in length
2165"^DD",1130580001.101,1130580001.101,.01,"DT")
21663101012
2167"^DD",1130580001.101,1130580001.101,.3,0)
2168MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
2169"^DD",1130580001.101,1130580001.101,.3,.1)
2170MEANINGFUL USE YEAR KEY
2171"^DD",1130580001.101,1130580001.101,.3,3)
2172Answer must be 1-30 characters in length.
2173"^DD",1130580001.101,1130580001.101,.3,"DT")
21743111201
2175"^DD",1130580001.101,1130580001.101,.5,0)
2176TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
2177"^DD",1130580001.101,1130580001.101,.5,.1)
2178MEASURE TITLE
2179"^DD",1130580001.101,1130580001.101,.5,3)
2180Answer must be 3-240 characters in length
2181"^DD",1130580001.101,1130580001.101,.5,"DT")
21823110430
2183"^DD",1130580001.101,1130580001.101,.61,0)
2184VERY LONG DESCRIPTION^1130580001.111^^6;0
2185"^DD",1130580001.101,1130580001.101,.7,0)
2186DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
2187"^DD",1130580001.101,1130580001.101,.7,.1)
2188QRDA DISPLAY NAME
2189"^DD",1130580001.101,1130580001.101,.7,3)
2190Answer must be 3-240 characters in length
2191"^DD",1130580001.101,1130580001.101,.7,"DT")
21923101012
2193"^DD",1130580001.101,1130580001.101,.8,0)
2194REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
2195"^DD",1130580001.101,1130580001.101,.8,.1)
2196REPORTING MEASURE NAME
2197"^DD",1130580001.101,1130580001.101,.8,3)
2198Answer must be 3-30 characters in length
2199"^DD",1130580001.101,1130580001.101,.8,"DT")
22003110615
2201"^DD",1130580001.101,1130580001.101,1,0)
2202NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2203"^DD",1130580001.101,1130580001.101,1,.1)
2204MEASURE NUMERATOR PATIENT LIST
2205"^DD",1130580001.101,1130580001.101,1,"DT")
22063101012
2207"^DD",1130580001.101,1130580001.101,1.1,0)
2208ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2209"^DD",1130580001.101,1130580001.101,1.1,"DT")
22103110805
2211"^DD",1130580001.101,1130580001.101,1.2,0)
[1486]2212NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2213"^DD",1130580001.101,1130580001.101,1.2,3)
2214Enter the reminder rule set to use for this measure.
2215"^DD",1130580001.101,1130580001.101,1.2,12)
2216If the type of the reminder list rule is a Rule Set.
2217"^DD",1130580001.101,1130580001.101,1.2,12.1)
2218S DIC("S")="I $P(^(0),U,3)=3"
2219"^DD",1130580001.101,1130580001.101,1.2,21,0)
2220^^5^5^3120716^
2221"^DD",1130580001.101,1130580001.101,1.2,21,1,0)
2222This is the numerator reminder rule set to use for the quality measure.
2223"^DD",1130580001.101,1130580001.101,1.2,21,2,0)
2224
2225"^DD",1130580001.101,1130580001.101,1.2,21,3,0)
2226The rule set is used to generate a patient list, which this package
2227"^DD",1130580001.101,1130580001.101,1.2,21,4,0)
2228referneces. The contents of the patient list will produce the count for
2229"^DD",1130580001.101,1130580001.101,1.2,21,5,0)
2230the measure. This count is for the numerator.
[1485]2231"^DD",1130580001.101,1130580001.101,1.2,"DT")
[1486]22323120716
[1485]2233"^DD",1130580001.101,1130580001.101,1.5,0)
2234NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2235"^DD",1130580001.101,1130580001.101,1.5,.1)
2236LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
2237"^DD",1130580001.101,1130580001.101,1.5,"DT")
22383110809
2239"^DD",1130580001.101,1130580001.101,1.51,0)
2240ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2241"^DD",1130580001.101,1130580001.101,1.51,.1)
2242NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
2243"^DD",1130580001.101,1130580001.101,1.51,"DT")
22443110809
2245"^DD",1130580001.101,1130580001.101,2,0)
2246DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2247"^DD",1130580001.101,1130580001.101,2,.1)
2248MEASURE DENOMINATOR PATIENT LIST
2249"^DD",1130580001.101,1130580001.101,2,"DT")
22503101012
2251"^DD",1130580001.101,1130580001.101,2.1,0)
2252ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2253"^DD",1130580001.101,1130580001.101,2.1,"DT")
22543110805
2255"^DD",1130580001.101,1130580001.101,2.2,0)
[1486]2256DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2257"^DD",1130580001.101,1130580001.101,2.2,3)
2258Enter the reminder rule set to use for this measure.
2259"^DD",1130580001.101,1130580001.101,2.2,12)
2260If the type of the reminder list rule is a Rule Set.
2261"^DD",1130580001.101,1130580001.101,2.2,12.1)
2262S DIC("S")="I $P(^(0),U,3)=3"
2263"^DD",1130580001.101,1130580001.101,2.2,21,0)
2264^^5^5^3120716^
2265"^DD",1130580001.101,1130580001.101,2.2,21,1,0)
2266This is the denominator reminder rule set to use for the quality measure.
2267"^DD",1130580001.101,1130580001.101,2.2,21,2,0)
2268
2269"^DD",1130580001.101,1130580001.101,2.2,21,3,0)
2270The rule set is used to generate a patient list, which this package
2271"^DD",1130580001.101,1130580001.101,2.2,21,4,0)
2272referneces. The contents of the patient list will produce the count for
2273"^DD",1130580001.101,1130580001.101,2.2,21,5,0)
2274the measure. This count is for the denominator.
[1485]2275"^DD",1130580001.101,1130580001.101,2.2,"DT")
[1486]22763120716
[1485]2277"^DD",1130580001.101,1130580001.101,3,0)
2278QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
2279"^DD",1130580001.101,1130580001.101,3,.1)
2280MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
2281"^DD",1130580001.101,1130580001.101,3,3)
2282Answer must be 3-120 characters in length
2283"^DD",1130580001.101,1130580001.101,3,"DT")
22843101012
2285"^DD",1130580001.101,1130580001.101,3.1,0)
2286QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
2287"^DD",1130580001.101,1130580001.101,3.1,.1)
2288QRDA SYSTEM OID (FIXED)
2289"^DD",1130580001.101,1130580001.101,3.1,9.01)
2290
2291"^DD",1130580001.101,1130580001.101,3.1,9.1)
2292S X="2.16.840.1.113883.3.249.12"
2293"^DD",1130580001.101,1130580001.101,3.1,"DT")
22943101012
2295"^DD",1130580001.101,1130580001.101,3.2,0)
2296QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
2297"^DD",1130580001.101,1130580001.101,3.2,.1)
2298QRDA MEASURE CODE
2299"^DD",1130580001.101,1130580001.101,3.2,3)
2300Answer must be 1-80 characters in length
2301"^DD",1130580001.101,1130580001.101,3.2,"DT")
23023101012
2303"^DD",1130580001.101,1130580001.111,0)
2304VERY LONG DESCRIPTION SUB-FIELD^^.01^1
2305"^DD",1130580001.101,1130580001.111,0,"DT")
23063101013
2307"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
2308
2309"^DD",1130580001.101,1130580001.111,0,"UP")
23101130580001.101
2311"^DD",1130580001.101,1130580001.111,.01,0)
2312VERY LONG DESCRIPTION^Wx^^0;1
2313"^DD",1130580001.101,1130580001.111,.01,.1)
2314LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
2315"^DD",1130580001.101,1130580001.111,.01,3)
2316LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
2317"^DD",1130580001.101,1130580001.111,.01,"DT")
23183101013
2319"^DIC",1130580001.101,1130580001.101,0)
2320C0Q QUALITY MEASURE^1130580001.101
2321"^DIC",1130580001.101,1130580001.101,0,"GL")
2322^C0Q(101,
2323"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
2324
2325**END**
2326**END**
Note: See TracBrowser for help on using the repository browser.